首页ATYR • NASDAQ
add
aTyr Pharma Inc
相关资讯
财务信息
损益表
收入
净收入
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
收入 | — | — |
经营支出 | 333.60万 | 25.93% |
净收入 | -1725.90万 | -52.20% |
净利润率 | — | — |
每股收益 | -0.23 | -15.00% |
息税折旧摊销前利润 | -1796.50万 | -44.42% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 6598.70万 | -35.39% |
总资产 | 9161.60万 | -26.75% |
负债总额 | 2647.70万 | -1.45% |
权益总额 | 6513.90万 | — |
发行在外的股份 | 8394.24万 | — |
市净率 | 3.47 | — |
资产回报率 | -45.92% | — |
资本回报率 | -52.14% | — |
现金流
现金净变动
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
净收入 | -1725.90万 | -52.20% |
来自运营的现金 | -1315.80万 | -37.65% |
投资现金 | 1794.60万 | 309.45% |
融资现金 | -10.50万 | -103.91% |
现金净变动 | 468.30万 | 287.77% |
自由现金流 | -648.64万 | -12.66% |
简介
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
成立时间
2005年1月1日
员工数量
58
